Submit Deal

AUDENTES THERAPEUTICS INC

Summary

Audentes Therapeutics operates as a biotechnology company. The Company focuses on the development and commercialization of gene therapy treatments for people with serious rare diseases.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 2.32 B

Avg. Deal Size£ 2.32 B

Market Context

Senior Management

Matthew R Patterson
Chairman and CEO
Tom Soloway
CFO
Natalie C Holles
President and COO

Sort

02 Dec 2019|United States|Biotechnology

Target: AUDENTES THERAPEUTICS INC

Bidder: ASTELLAS PHARMA INC

8 Service Providers

4 Target | 4 Bidder

73 Dealmakers

34 Target | 39 Bidder

£ 2.32 B

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy